membranes, such as P-selectin (CD62P), which recruits neutrophils, monocytes and lymphocytes via its ligand, P-selectin glycoprotein ligand-1 (PSGL-1). 3, 5 Platelets store intracellular immune-associated molecules, such as α-granules, which are dense granules containing inflammatory cytokines. 1 Platelets destroy pathogens and directly induce bronchoconstriction through the antimicrobial proteins in the α-granules, such as platelet factor 4 (PF4) and the pathogenic cytokines. 1, 6 The surface molecules of platelets bind to the surfaces of neutrophils, eosinophil and lymphocytes via ligands, thereby forming platelet-adherent leucocytes that subsequently amplify cysteinyl leukotriene (LT) production. 7 Platelets store interleukin (IL)-33, which is crucial for eosinophilic inflammation in the asthma mouse model. 8 The hypertrophic factors and extracellular matrix enzymes released from platelets induce smooth muscle hyperplasia and collagen deposition as features of airway remodelling. 2 Increasing evidence has shown the role of platelets in asthma.
Platelets are more activated in patients with bronchial asthma than in healthy controls, 9, 10 although some patients present a mild haemostatic defect. 11, 12 Activated platelets release intracellular mediators and produce microparticles, which increase in patients with asthma. 13, 14 A randomized, double-blind, placebo-controlled crossover study demonstrated that prasugrel slightly improves airway responsiveness to mannitol. 15 The association between platelets and eosinophils has been partially elucidated. Activated platelets adhere to eosinophils through P-selectin/PSGL-1, CD40/CD40L and glycoprotein IIb/IIIa/MAC-1, 8 forming platelet-eosinophil aggregations (PEA). Additionally, plateletleucocyte aggregations increase after allergen challenge, and the percentages of eosinophil-bound P-selectin and eosinophil-bound αIIb are correlated with the lung function of patients with asthma. 16 Platelets and eosinophils share similar surface receptors, including the cysteinyl LT receptor type 1 (CysLTR1) and the P2Y12 purinergic receptor (P2Y12R). Adenosine diphosphate (ADP), a specific platelet activator, triggers degranulation of eosinophils through P2Y12R. 17 Our recent study suggested an inhibitory effect of clopidogrel (Clo), an antiplatelet drug that targets the P2Y12R, during eosinophilic inflammation and degranulation. 18 Furthermore, LTE 4 , a P2Y12R and CysLTR1 agonist, induces eosinophilic inflammation following a platelet-dependent mechanism. 19 We have suggested that LTE 4 amplifies the activation of platelets and eosinophils, thereby initiating the PEA and subsequent airway inflammation. Furthermore, co-administering antagonists of CysLTR1 (montelukast, [Mon] ) and P2Y12R (Clo) may synergistically enhance the treatment of allergic asthma. Therefore, we established an eosinophilic asthma mouse model and evaluated the synergistic effect of these two drugs. We also investigated the mechanism of the synergistic effect.
| MATERIAL S & ME THODS

| Species and ethics statement
Female BALB/c mice (6 weeks old; weight, 20 ± 2 g) were obtained from the Jackson Laboratory (Bar Harbor, ME). The animals were housed under specific pathogen-free conditions and were maintained on a 12-hour light/dark cycle with food and water provided ad libitum. 
| Airway resistance measurement and sample collection
The FlexiVent system (Scireq, Montreal, QC, Canada) was applied to measure airway resistance. On the indicated day, the mice were anaesthetized with pentobarbital sodium and intubated with a cannula. After connecting the mice to a computer-controlled smallanimal ventilator, the mice were ventilated with a tidal volume of 
| Measurement of cytokine levels
The were measured using the Leukotriene E4 ELISA Kit (Cayman Chemical, Ann Arbor, MI).
| Identification of PEA in BAL fluid and whole blood of mice
Flow cytometry of PEA in whole blood was performed as described previously. 20, 21 Mouse whole blood was harvested by cardiac puncture into tubes containing 3.8% sodium citrate to prevent coagulation.
The whole blood was incubated with phycoerythrin (PE) 
| Isolation of mouse eosinophil and platelets
The mouse eosinophils were isolated using a previous protocol with some modifications. 23 medium supplemented with 10% foetal bovine serum, 100 U/mL penicillin G sodium, and 100 µg/mL streptomycin sulphate (all from Gibco, Grand Island, NY) until further experiments were conducted ( Figure S1 ).
In parallel, mouse platelets were isolated as described previously. 20 . Whole blood was centrifuged at 1000 g for 15 minutes at RT. The platelet-rich plasma (PRP) was collected and centrifuged at 400 g for 10 minutes at RT to isolate the platelets. The cells were primed with CaCl 2 (Sigma Aldrich) (final concentration = 5 mmol/L) for 10 minutes prior to the experiment.
| In vitro PEA assay
Based on platelets and eosinophils having the same ligands, 24 B, Total and differential cell counts were calculated using a haemocytometer. P values were analysed by one-way ANOVA with Tukey's post-hoc test. *, **, and *** indicate P < 0.05, 0.01 and 0.001, respectively, in the comparisons between the indicated groups; # P < 0.05 in comparisons involving the drug-treated groups; NS, not significant signals were analysed immediately by flow cytometry, as described in the previous section, and at least 1000 events were recorded.
| Antibodies and reagents
The antibodies used against the mouse target proteins were anti-P- 
| Statistical analysis
| Clo/Mon decreases the levels of Th2 cytokines and platelet and eosinophil activation markers
| Clo/Mon reduces the number of inflammatory cells and the mucus production in lung tissues
Clopidogrel and montelukast attenuated the number of inflammatory cells in lung tissues (P < 0.05) ( Figure 3A) . Additionally, in the asthmatic mice, Clo/Mon improved mucus secretion more effectively than the single treatment (P < 0.05) ( Figure 3B ).
| Suppressive effect of Clo/Mon on PEA formation is superior to that of Dex
Platelet-eosinophil aggregation in mouse whole blood was visualized CysLTR1 to P2Y12R ratio in our previous study, 25 we combined Mon and Clo (Clo/Mon) at a ratio of 1:1. We used considerably lower doses of Mon and Clo (10 mg/kg for each drug) compared to previous experimental studies. 18, 26, 27 The secondary, eosinophilic asthma mouse model manifested higher eosinophilic infiltration than the model that we used previously to clearly detect the therapeutic effects of Clo/Mon. The Clo/Mon treatment suppressed the lymphocyte count in BAL fluid, which explained the decreased levels of Th2 cytokines.
In agreement with the hypothesis, Clo/Mon synergistically inhibited not only PEA formation but also activation of platelets (PF4) and eosinophils (EPX). The symbiotic association between platelets and eosinophils was reinforced in our study. Platelets and eosinophils interact through direct contact via surface ligands (eg, P-selectin) or soluble mediators, leading to cellular activation.
Platelets express both high-and low-affinity IgE receptors, which may be functional in asthma. 1, 2, 28 Numerous studies have demonstrated increased PEA after an allergen challenge in asthmatics. 29, 30 Platelet and eosinophil activities correlate positively in asthmatic patients and negatively with asthma-related quality of life. 30 In the current study, the increase in PEA formation was impaired by Clo/ Mon, possibly resulting in reduced eosinophil recruitment to lung tissues. Moreover, the adherent platelets from the PEA were more activated, leading to the release of PF4, which further triggers the activation and accumulation of eosinophils. 7, 31 Indeed, the percentage of PEA correlated positively with PF4 level and eosinophil count. We found increased levels of PF4 (CXCL4) and EPX released from the α-granules of activated platelets, which is a known potent eosinophil chemoattractant and an augmentative agent for eosinophil adhesion. 2, 32 In our study, the increased PF4 in asthmatic mice enhanced the eosinophilia, which might amplify EPX production although we could not find any direct relationship between EPX and PF4.Notably, PF4 and EPX contribute directly to the induction of airway hyperactivity in animal models. 33, 34 Thus, we speculate that the inhibitory effects of Clo/Mon may rely on interactions between platelets and eosinophils.
Next, we investigated the mechanism by which Clo/Mon exerted their effects. Several stimulators of platelet activation have been reported, including ADP and LTC 4 . 35, 36 Adenosine diphosphate was the most potent agonist to induce PEA formation and P-selectin overexpression, followed by LTE 4 . We could not demonstrate the effects of LTC 4 on platelet activation, which were demonstrated previously, 35 possibly due to the prolonged activation of platelets during the induction period in our asthma mouse
Correlations between platelet-eosinophil aggregations (PEA) and eosinophil counts with inflammatory mediators and leukotriene E4 (LTE 4 ). Platelet-eosinophil aggregations correlated with (A) bronchoalveolar lavage fluid (BALF) level of platelet factor 4 (PF4) and (B) eosinophil count in BALF. The eosinophil count also correlated with BALF levels of (C) PF4, (D) eosinophil peroxidase (EPX), and (E) LTE 4 . Analyses were performed by Spearman's rank correlation coefficient model. Clopidogrel and montelukast suppressed ADP-induced PEA formation and P-selectin expression. Therefore, an addition of P2Y12R supports the effect of Mon in suppressing eosinophil protease activity and infiltration. 41 It is intriguing that LTE 4 also induced PEA formation independent of the P-selectin ligand. We determined that LTE 4 levels increased significantly in asthmatic mice, which is inline with previously reported results. 42 Eosinophil count correlated positively with BALF LTE 4, which reinforce that eosinophils are the major source of LTE 4.
The increased level of LTE 4 could also be a consequence of PEA formation because LTC 4 synthase from platelets amplifies CysLT production by eosinophils, 7 subsequently rendering PEA by another mechanism, such as through a P2Y12R-or CysLTR1-dependent pathway. Suppressing the increase in LTE 4 and PEA by Clo/
Mon is more relevant in aspirin-exacerbated respiratory disease, which is a severe clinical phenotype of asthma characterized by LT overproduction and eosinophilia.
In conclusion, Clo operated synergistically with Mon to diminish the platelet-eosinophil interaction and platelet-dependent eosinophil recruitment and degranulation, thereby attenuating airway inflammation and LTE 4 production from eosinophils in the asthma model. 
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